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False Homozygosity Results in HLA Genotyping due to Loss of 
Chromosome 6 in a Patient with Acute Lymphoblastic Leukemia
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Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul Korea 
Loss of heterozygosity (LOH) in chromosome 6p has been reported in a number of tumors and some hematologic malignancies, 
including ALL. LOH in chromosome 6p, on which the HLA genes are located, can give rise to false homozygosity results in HLA ge-
notyping of patients with hematologic malignancies. Here we report false homozygosity results in HLA genotyping due to the loss 
of whole chromosome 6 in the neoplastic cells of a patient with ALL. A 33-yr-old Korean female patient was admitted for the evalua-
tion of leukocytosis detected during a workup for headache. Her initial white blood cell count was 336.9×10
9/L with 84% of blasts in 
the differential count. Precursor-B lymphoblastic leukemia was diagnosed from a subsequent bone marrow study. HLA high-reso-
lution genotyping of the patient was requested at the time of diagnosis for possible hematopoietic stem cell transplantation. Ho-
mozygosity results (A*02:01, B*54:01, C*08:01, DQB1*04:01) were obtained, except for the DRB1 locus (DRB1*04:05, DRB1*11:01), 
in sequence-based typing. Conventional karyotyping of bone marrow metaphase cells revealed chromosomal abnormalities, with 
loss of multiple chromosomes including chromosome 6, and reduplication of the remaining chromosomes: 29,X,+X,+8,inv(9)(p11
q13),+10,+14,+18,+21[15]/58,idemX2[3]/46,XX,inv(9)[2]. LOH at the HLA region was suspected and HLA genotyping was repeated 
with the peripheral blood in remission state after induction chemotherapy. All 5 HLA loci were typed as heterozygous (A*02:01, 
A*02:06, B*40:01, B*54:01, C*03:04, C*08:01, DRB1*04:05, DRB1*11:01, DQB1*03:01, DQB1*04:01). To avoid false HLA typing re-
sults in patients with hematologic malignancies, clinicians, as well as laboratory personnel, need to be aware of such problems and 
take appropriate precautions. 
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INTRODUCTION
The MHC is a genomic region located on the short arm 
of chromosome 6 (6p), encoding HLA molecules. Loss or 
down-regulation of MHC class I expression in cancer cells 
is a major immune escape route used by a large variety of 
human tumors to evade anti-tumor immune responses me-
diated by cytotoxic T lymphocytes [1-3]. Multiple mecha-
nisms are responsible for such HLA class I alterations [4-11]. 
Among them, loss of heterozygosity (LOH) of chromosome 
6p has been reported in a number of solid tumors and some 
hematologic malignancies, mainly in ALL [12, 13].
In patients with leukemia, LOH at the MHC region can 
give false homozygosity results in HLA typing when the 
typing is performed using peripheral blood containing a 
high proportion of leukemic cells. However, such a problem 
has rarely been reported because HLA typing is not usually 
carried out on a blood specimen containing a high propor-
tion of neoplastic cells. A case of a CLL patient has been re-
ported involving LOH at the MHC region at the initial HLA 
typing, which was then detected at confirmatory typing for 
hematopoietic stem cell transplantation [14]. Here we re-
port false homozygosity results in HLA genotyping due to 
LOH associated with the loss of whole chromosome 6 in an 
adult Korean patient with ALL. 
CASE REPORT
A 33-yr-old Korean female was admitted to the hemato-
oncology ward of Seoul National University Hospital on 
October 4, 2010 for the evaluation of leukocytosis found Park H, et al.  •  False HLA Homozygosity Results in ALL 
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during a workup for headache. A complete blood cell count 
showed a hemoglobin level of 7.8 g/dL, a platelet count of 
15×10
9/L, and a white blood cell count of 336.9×10
9/L, of 
which 84% were blasts. Bone marrow aspirates showed hy-
percellularity with 99.6% of blasts. The blasts were homoge-
neously small sized with high nuclear/cytoplasmic ratio and 
inconspicuous nucleoli. Flow cytometric analysis revealed 
that the neoplastic cells were positive for TdT, CD19, CD34, 
and cytoplasmic CD79a, and a diagnosis of precursor-B ALL 
was made. 
On October 7, 2010 (the third day of hospitalization), be-
fore initiation of induction chemotherapy, high-resolution 
HLA DNA typing of the patient was performed using the 
peripheral blood sample. For future hematopoietic stem cell 
transplantation, HLA class I (A, B, and C) serological typing 
of her 2 siblings was also carried out. High-resolution HLA 
typing was performed by sequence-based typing (SBT) us-
ing the AlleleSEQR
® HLA Sequencing kit (Atria Genetics, 
South San Francisco, CA, USA). HLA genotyping of the 
patient revealed homozygosity at class I and II loci, except 
for the DRB1 locus: A*02:01, B*54:01, C*08:01, DRB1*04:  
05, DRB1*11:01, DQB1*04:01 (Table 1, Fig. 1). One of the 
deduced HLA haplotypes (A*02:01-B*54:01-C*08:01-DR-
B1*11:01-DQB1*04:01) of the patient was a fairly unusual 
one for Korean ethnicity. Moreover, homozygosity at the 
HLA-B locus (B*54:01) in the patient could not be explain  ed, 
considering the HLA-B types of her 2 siblings (B51, B54 in 
one and B60, B62 in the other). Retyping of the patient’s 
DNA for HLA-A, -B, and -DR loci by the sequence specific 
oligonucleotide (SSO) method using Dynal RELI
TM SSO 
Table 1. HLA sequence-based typing results of the patient using blood sam-
ples obtained at the time of diagnosis and in a remission state, and serotyp-
ing results of her 2 siblings
Date tested Patient
Oct. 7, 2010*
Brother
Oct. 6, 2010
Sister
Oct. 11, 2010
Patient
Dec. 13, 2010
†
HLA-A  A*02:01 (A2) A2 A2  A*02:01 (A2)
blank blank A26 A*02:06 (A2)
HLA-B  B*54:01 (B54) B51 B60 B*40:01 (B60)
blank B54 B62 B*54:01 (B54)
HLA-C C*08:01 (Cw8) Cw8 Cw3 C*03:04 (Cw3)
blank blank blank C*08:01 (Cw8)
HLA-DRB1  DRB1*04:05 Not tested Not tested DRB1*04:05
DRB1*11:01 DRB1*11:01
HLA-DQB1  DQB1*04:01 Not tested Not tested DQB1*03:01
blank DQB1*04:01
*Initial blood sample (87% blasts) obtained before induction chemotherapy; 
†Blood 
sample (0% blasts) obtained in a remission state after chemotherapy. HLA alleles that 
were falsely not detected in the initial blood sample are in bold.
HLA-B, -DRB, and -DQB1 kits (Invitrogen, Wirral, UK) also 
revealed homozygosity at the following loci: HLA-B*54:01 
group, DRB1*04:05 group (DRB4*01:01 group), and DQ-
B1*04:01 group. A retrospective review revealed that the 
patient’s HLA genotyping had been requested when she had 
a high blast count in the peripheral blood, with a white blood 
cell count of 91.7×10
9/L, of which 87% were blasts.
Conventional karyotyping performed on a bone marrow 
aspirate sample obtained on October 11, 2010 (the seventh 
day of hospitalization) revealed chromosomal abnormali-
ties with loss of multiple chromosomes, including chromo-
some 6, and reduplication of the remaining chromosomes: 
Fig. 1. Sequence-based typing of HLA-B and -DRB1 genes at the time of di-
agnosis (A, B) and at remission (C, D). HLA alleles detected were: (A) B*54:01; 
(B) DRB1*04:05, *11:01; (C) B*40:01, *54:01; (D) DRB1*04:05, *11:01. At 
the time of diagnosis, the minor HLA-B allele (B*40:01) shows amplification 
peaks indistinguishable from background noise (A), whereas the minor HLA-
DRB1 allele (DRB1*11:01) shows lower but discernible amplification peaks 
(B). At remission, both HLA-B and -DRB1 loci show heterozygosity with simi-
lar amplification peaks for the 2 alleles. E2F and E2R represent exon 2 forward 
and exon 2 reverse, respectively.
HLA-B
E2F
E2R
E2F
E2R
E2F
E2R
E2F
E2R
HLA-DRB1
c.204 c.206
A
C
B
D
cDNA 203 204 205 206 207 258    259 260 261  262
B*40:01:01 G   G   A   A   G
B*54:01:01 G   A   G   G   G
DRB1*04:05:01 C   G   C   C  G
DRB1*11:01:01 T   G  A   G   G304     www.kjlm.org
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29,X,+X,+8,inv(9)(p11q13),+10,+14,+18,+21[15]/58,idem
X2[3]/46,XX,inv(9)[2] (Fig. 2). Retrospective analysis of 
short tandem repeat (STR) markers revealed LOH in the 
STR markers on chromosomes 3, 4, 5, 7, 12, and 13 (Table 
2), which was in accordance with conventional karyotyping 
results. Minor alleles due to loss of pertinent chromosomes 
in neoplastic cells comprised on average 4.1% (range 2.9-
6.9%). 
False homozygosity results due to LOH at the HLA re-
gion were suspected. HLA genotyping was repeated on De-
cember 13, 2010, with the peripheral blood in a remission 
state, 67 days after the initiation of induction chemotherapy. 
A complete blood cell count showed a hemoglobin level of 
10.0 g/dL, a platelet count of 160×10
9/L, and a white blood 
cell count of 2.3×10
9/L, of which 0% were blasts. All of the 
HLA-A, -B, -C, -DRB1, and -DQB1 loci were typed as het-
erozygous: A*02:01, A*02:06, B*40:01, B*54:01, C*03:04, 
C*08:01, DRB1*04:05, DRB1*11:01, DQB1*03:01, DQ-
B1*04:01 (Table 1, Fig. 1). Karyotyping performed on a pe-
ripheral blood sample obtained on the same date (in a re-
mission state) revealed a normal karyotype: 46,XX,inv(9)
(p11q13)[20]. STR analysis performed on the same blood 
sample also revealed heterozygosity results in all 9 markers. 
Thus the heterozygosity results of HLA-A, -B, -C, -DR, and 
-DQ loci were confirmed and finally used to search for an 
unrelated donor for bone marrow transplantation. 
DISCUSSION
HLA class I antigens are vital in the recognition of tumor 
cells by tumor-specific cytotoxic T lymphocytes. Loss or 
down-regulation of HLA class I antigens, therefore, repre-
sents a way by which tumors can escape T-cell surveillance, 
adversely affecting the course of disease and the outcome of 
T-cell-based immunotherapy [1-3]. This can have several 
causes: absence of β2-microglobulin or transporter associ-
ated with antigen processing (TAP) expression [4-6]; loss of 
1
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Fig. 2. Initial karyotyping of G-banded bone marrow metaphase cells showing loss of multiple chromosomes including chromosome 6 (A) and reduplication of 
the remaining chromosomes (B).
Table 2. Results of the short tandem repeat (STR) analysis of 9 loci using pa-
tient’s DNA at the time of diagnosis and in a remission state
STR marker Chromosomal 
location
Allelic range 
(repeats)
Percentage (%)
Oct. 7, 2010* Dec. 13, 2010
†
D13S317 13q22-q31 8 96.0  50.9
10 4.0 49.1
D18S51 18q21.3 15 51.5  50.5
17 48.5  49.5
D21S11 21q21.1 30 50.9  51.3
31 49.1  48.7
D3S1358 3q21 16 97.1  50.0
18 2.9 50.0
D5S818 5q21-q31 11 6.9 50.6
12 93.1  49.4
D7S820 7q 8 3.8 52.1
11 96.2  47.9
D8S1179 8q24.1-24.2 13 50.6  50.0
15 49.4  50.0
FGA 4q28 22 96.5  51.5
24 3.5 48.5
vWA 12p13.31 14 3.4 50.3
18 96.6  49.7
*Initial blood sample (87% blasts) obtained before induction chemotherapy. Minor 
alleles (average 4.1%, range 2.9-6.9%) due to loss of pertinent chromosomes in neo-
plastic cells (Fig. 2) are in bold; 
†Blood sample (0% blasts) obtained in a remission state 
after chemotherapy.Park H, et al.  •  False HLA Homozygosity Results in ALL 
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heterozygosity, large deletions, or mitotic recombination in 
chromosome 6 [4, 8, 9]; transcriptional down-regulation 
[10]; or point mutation, partial deletion, or somatic recom-
bination [4, 7, 11].
LOH in chromosome 6p has been detected in about 10-
55% of solid tumors such as those of the colon or larynx, 
melanoma, and breast cancer [12, 15]. Previously reported 
frequencies of LOH in 6p in hematologic malignancies are 
variable according to the detection method and definition 
of LOH. Masuda et al. reported loss or down-regulation of 
HLA class I expression in only 4 out of 43 freshly isolated 
adult hematologic malignancy samples and no haplotype 
loss in the HLA genome [16]. In childhood ALL, the fre-
quency of LOH in 6p has been reported to be 7-8% [17, 18]. 
In contrast, McEvoy et al. reported a high frequency of MHC 
LOH in ALL patients (19/56), which was usually associated 
with whole chromosome 6 loss (13/19) [13].
LOH in chromosome 6p in hematologic malignancies 
can cause false homozygosity results in HLA genotyping 
when the typing is performed with leukemic blood samples. 
This can give rise to a serious problem in hematopoietic 
stem cell transplantation in that the patient would be at a 
risk of being transplanted from a falsely matched donor if 
the false typing results are not properly recognized. Sero-
logic typing of HLA antigens with blood samples contain-
ing high blast counts is difficult, and therefore, typing is 
usually not attempted. Nowadays DNA typing is increas-
ingly used for HLA typing, and such problems may occur if 
clinicians inappropriately order HLA genotyping with leu-
kemic blood samples, and the HLA typing laboratory is not 
aware of the problem in the blood sample requested for typ-
ing. False homozygosity results for HLA class I due to LOH 
at the MHC region has been reported in a CLL patient, which 
was detected at confirmatory typing for hematopoietic stem 
cell transplantation [14]. In this patient, LOH in chromo-
some 6p was confirmed by microarray-based comparative 
genomic hybridization of tumor cells. 
In our case, whole chromosome 6 loss in leukemic cells 
caused false homozygosity results in HLA-A, -B, -C, and 
-DQB1 SBT and HLA-B, -DRB, and -DQB1 SSO typing. Re-
testing with a peripheral blood sample in a remission state 
using SBT revealed heterozygosity results in all of the 5 HLA 
loci tested. In HLA-DRB1 typing in the initial sample, a het-
erozygosity result was obtained by SBT and homozygosity 
result by SSO typing. A sequencing electropherogram show  ed 
amplification peaks of the minor allele (DRB1*11:01, pres-
ent only in a small fraction of normal leukocytes) which were 
much lower than those of the major allele (DRB1*04:05, pre-
sent in both leukemic blasts and normal leukocytes) (Fig. 1). 
As for the discrepancy in HLA-DRB1 typing results between 
the 2 typing methods, differences in the primers used for 
these methods might be the cause. For HLA-DRB1-specific 
amplification, different HLA-DRB1 alleles cannot be ampli-
fied by a single pair of primers and thus several different 
primer pairs amplifying different groups of DRB1 alleles are 
used in HLA-DRB1 SBT. The primer pairs that can amplify 
each of the 2 DRB1 alleles (DRB1*04:05, *11:01) in this pa-
tient are expected to be different and the minor allele could 
thus be amplified in SBT. In HLA-DRB SSO typing, using a 
Dynal RELI
TM SSO kit, single primer pairs amplifying DRB1/ 
DRB3/DRB4/DRB5 genes are used, and the minor allele in 
this patient seems not to have been effectively amplified to 
be detected. Likewise, minor alleles in HLA-A, -B, -C, and 
-DQB1 loci in this patient seem not to have been effectively 
amplified to be detected by SBT. Thus, when HLA typing is 
performed on blood samples containing a high proportion 
of blasts with LOH in chromosome 6p, typing results may 
differ between different typing methods according to differ-
ences in their detection sensitivity. In the PCR-sequence 
specific primer (SSP) method, different primer pairs am-
plify different HLA alleles, and this method is expected to 
detect minor alleles with higher sensitivity than the SSO or 
SBT methods. We later performed PCR-SSP typing (AllSet 
Gold SSP HLA typing kit, Invitrogen, Brown Deer, WI, USA) 
for HLA-B (48 primer pairs) and -DR loci (24 primer pairs) 
using the DNA sample from our patient at the time of diag-
nosis. As expected, the PCR-SSP method detected hetero-
zygosity for both HLA-B and -DR loci, although the minor 
alleles showed much weaker amplification bands on the elec-
tropherogram than the major alleles.
To avoid false HLA typing results in patients with hema-
tologic malignancies, clinicians as well as laboratory person-
nel need to be aware of such problems and take appropriate 
precautions. In leukemia patients, HLA typing is usually per-
formed at the time of diagnosis or during the first complete 
remission [19]. Clinicians should not request HLA typing 
using blood samples at the time of diagnosis if patients have 
blasts in the peripheral blood. There is no data available on 
what percentage of blasts or neoplastic cells in the white cell 
differential count of a peripheral blood sample can be pres-
ent without affecting the HLA molecular typing results in 
patients with LOH in 6p. Because blasts generally have con-
siderably larger nuclei than normal leukocytes, the DNA 
fraction from blasts would comprise a much larger portion 
of total DNA extracted from leukocytes than that simply 
calculated from the percentage of blasts in the blood sam-
ple. This is evidenced in our case; whereas the blood sample 
used for HLA DNA typing contained 87% blasts, the minor 306     www.kjlm.org
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alleles detected by STR analysis comprised a much lower 
percentage (average 4.1%) than expected (above 10%). If 
HLA typing is required in such patients before remission is 
obtained, alternative samples, such as a buccal swab or hair 
follicles, should be considered for HLA typing. HLA typing 
laboratories involved in the typing of patients with hemato-
logic malignancies should be aware of such problems and 
should check patients’ hematologic data whenever they have 
unusual HLA typing results or discrepancies between dif-
ferent typing methods. In addition, the patients’ HLA typing 
results should be reconfirmed by confirmatory typing. For 
hematopoietic stem cell transplantation, confirmatory HLA 
typing using newly collected samples should be performed 
not only for donors but also for patients [20, 21]. How  ever, 
confirmatory HLA typing of patients is not reimbursed by 
the national medical insurance system and is not routinely 
carried out as a standard clinical practice in this country. 
We have described a case of false homozygosity results in 
HLA genotyping in a patient with precursor-B ALL due to 
the loss of whole chromosome 6 in the neoplastic cells. To 
avoid false HLA typing results in patients with hematologic 
malignancies, clinicians and HLA typing laboratory per-
sonnel need to be aware of the problem and take appropri-
ate precautions. HLA typing should not be performed with 
blood samples containing a high proportion of neoplastic 
cells, and alternative samples of buccal swab or hair follicles 
should be used if needed. In addition, confirmatory HLA 
typing should be routinely performed for hematopoietic 
stem cell transplantation.
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